Lv1
98 积分 2025-02-25 加入
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
2个月前
已完结
Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex
2个月前
已完结
Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism
3个月前
已完结
Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism
3个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
3个月前
已完结
hiPSC‐derived hepatocytes closely mimic the lipid profile of primary hepatocytes: A future personalised cell model for studying the lipid metabolism of the liver
4个月前
已完结
P18-26 Development of CYP1A1-mCherry hiPSC-derived hepatic organoids for enhanced sensitivity to AHR agonists
4个月前
已关闭
Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism
4个月前
已完结
A Unified Mechanistic Framework for Metabolism-Based Therapeutics in MASH: A Comprehensive Review of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Statins
4个月前
已关闭
Structural characterisation of Cistanche tubulosa polysaccharides and their effects against non-alcoholic steatohepatitis via gut microbiota regulation
5个月前
已完结
皖公网安备34019202002308
